Lucinda Quan
Founder at ALIGOS THERAPEUTICS, INC.
Net worth: 314 770 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lawrence Blatt | M | 62 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 19 years |
| Jack Nielsen | M | 60 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 13 years |
| Inge Thulin | M | 69 | 6 years | |
| Carole Nüchterlein | F | 62 | 6 years | |
| K. Hirth | M | 72 | 6 years | |
| Jim Scopa | M | 65 | 3 years | |
| Bridget Martell | M | 58 | 3 years | |
| Jennifer Zachary | F | 46 | 6 years | |
| Jordyn Tarazi | F | - | - | |
| Carla Fiankan | F | - | 13 years | |
| Sushmita M. Chanda | M | 58 | 6 years | |
| Julian Symons | M | 63 | 6 years | |
| Lesley Calhoun | F | 58 | 4 years | |
| Peter Dannenbaum | M | - | 7 years | |
| Eric Rubin | M | 65 | 6 years | |
| Dean Li | M | 62 | 7 years | |
| Kristina Engeseth | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Leonid Beigelman | M | 66 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 15 years |
| John C. Hodgman | M | 69 | - | |
| Jean-Jacques Bienaimé | M | 70 | 2 years | |
| Paul D. Arata | M | 69 | - | |
| Thomas Woiwode | M | 52 | 5 years | |
| Lars Ekman | M | 74 | 7 years | |
| Peter Moldt | M | 65 | - | |
| Frank Verwiel | M | 62 | 2 years | |
| Kathleen Glaub | F | 70 | - | |
| John Noseworthy | M | 71 | - | |
| Angus Russell | M | 68 | 3 years | |
| Jonathan Leff | M | 55 | 12 years | |
| David Kabakoff | M | 76 | 9 years | |
| Charles Kidder | M | 79 | 12 years | |
| Natarajan Sethuraman | M | 62 | 10 years | |
| Sheila Ranganath | F | - | 5 years | |
| Louis C. Drapeau | M | 79 | 7 years | |
| Andrew Powell | M | 66 | 2 years | |
| Francesco Maria Lavino | M | 51 | 2 years | |
| Nancy Miller-Rich | F | 65 | 4 years | |
| Fariborz Kamal | M | 61 | 2 years | |
| Kimberly Park | F | 60 | 4 years | |
| Maria Rivas | M | 60 | 2 years | |
| Arthur Santora | M | 73 | 28 years | |
| Joseph Eid | M | 56 | - | |
| Daniel Pascheles | M | - | 11 years | |
| Roger Dansey | M | 67 | 3 years | |
| Rongqiang Liu | M | 58 | 4 years | |
| Ken Johnson | M | 61 | 1 years | |
| Robert Plenge | M | 53 | 4 years | |
| Karen Akinsanya | M | 56 | 4 years | |
| Matthew McClure | M | 53 | 5 years | |
| Yuan Xu | M | 56 | 2 years | |
| Reshma Rangwala | M | 46 | 5 years | |
| John Fry | M | - | 5 years | |
| Le-Van Nguyen | F | - | 2 years | |
| Christopher Galloway | M | 53 | 2 years | |
| John Renger | M | 55 | 15 years | |
| Marvin Johnson | M | 61 | 2 years | |
| Lisa LeCointe-Cephas | F | 42 | 6 years | |
| Joseph Arena | M | 69 | 1 years | |
| Elizabeth Ann Fagan | M | 74 | 4 years | |
| Srikanth Venkatraman | M | - | 4 years | |
| Soren Christiansen | M | 68 | 19 years | |
| Quentin Roach | M | 57 | 4 years | |
| Amy Klug | F | - | - | |
| Arnaub Chatterjee | M | - | 5 years | |
| Jay Galeota | M | 57 | 28 years | |
| Rosanne Roth | F | - | 2 years | |
| Michel Vounatsos | M | 62 | 20 years | |
| Roy Baynes | M | 69 | - | |
| Roger L. Hawley | M | 71 | 3 years | |
| Steven Bryant Porter | M | 66 | 11 years | |
| Thomas Kassberg | M | 63 | 3 years | |
| Norman L. Halleen | M | 70 | 2 years | |
| Cynthia Y. Robinson | M | 65 | 3 years | |
| Willie Deese | M | 68 | 12 years | |
| Jonathan Leff | M | 66 | 3 years | |
| Alan Howard Cohen | M | 63 | - | |
| Sean Nolan | M | 56 | 2 years | |
| William Halter | M | 63 | 4 years | |
| Jennifer D. Haldeman | F | 59 | 1 years | |
| Karen S. Wright | F | 69 | 2 years | |
| Heath Lukatch | M | 56 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 5 years |
| Michael Rosenblatt | M | 76 | 32 years | |
| Michael Holston | M | 61 | 6 years | |
| Guy Patrick M. Eiferman | M | - | 4 years | |
| Bruce W. Tomlinson | M | 64 | 5 years | |
| Mathai Mammen | M | 57 | 1 years | |
| Mary Shoemaker | F | 63 | 1 years | |
| Barrett S. McGrath | M | - | - | |
| Erik Harris | M | 54 | 1 years | |
| Simon D. Kelner | M | 51 | 13 years | |
| Marianne A. Porter | M | 69 | 10 years | |
| Clark Golestani | M | 57 | 24 years | |
| Steven Mizell | M | 64 | 8 years | |
| Malcolm McKay | M | - | 4 years | |
| Phillip Samayoa | M | 37 | - | |
| Andrew Davis | M | 38 | 1 years | |
| Renu Vaish | F | - | 1 years | |
| Thomas Cannell | M | 62 | 1 years | |
| Jonathan Robbins | M | - | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lucinda Quan
- Personal Network
